GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT01589523
First received: April 3, 2012
Last updated: July 3, 2014
Last verified: July 2014

April 3, 2012
July 3, 2014
February 2006
December 2020   (final data collection date for primary outcome measure)
Evaluation of Atypical Bile Acid Metabolites [ Time Frame: Comparison between baseline and follow-up visits at 3, 6 and 12 months for the first year and then an average of yearly visits for at least 10 years. ] [ Designated as safety issue: No ]
Determination of changes in synthesis of atypical bile acids in urine by mass spectrometry (FAB MS)
Same as current
Complete list of historical versions of study NCT01589523 on ClinicalTrials.gov Archive Site
  • Liver Function tests [ Time Frame: Comparison between baseline and follow-up visits at 3, 6 and 12 months for the first year and then an average of yearly visits for at least 10 years. ] [ Designated as safety issue: No ]
    Liver function tests to include: total and direct bilirubin, ALT, AST, GGT, alkaline phosphatase, cholesterol, albumin, prothrombin time
  • Fat Soluble Vitamin Malabsorption [ Time Frame: Comparison between baseline and follow-up visits at 3, 6 and 12 months for the first year and then an average of yearly visits for at least 10 years. ] [ Designated as safety issue: No ]
    Measure Vitamin E and 25OH Vitamin D to assess vitamin absorption status
  • Growth parameters [ Time Frame: Standard of care (an average of every 6-12 months). ] [ Designated as safety issue: No ]
    Determine growth rate with height, weight and head circumference
  • Safety Assessments [ Time Frame: 3 months after initiation of therapy and then an average of yearly or more frequently as standard of care for at least 10 years. ] [ Designated as safety issue: Yes ]
    Incidence and severity of adverse events
Same as current
Not Provided
Not Provided
 
GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
Conjugated Cholic Acid for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-Chain Conjugation

The purpose of this research study is to determine the way (mechanisms) by which your defect in bile acid handling (metabolism) causes your liver disease or abnormality in absorption of vitamins and the effect of an investigational bile acid therapy (glycocholic acid) on your vitamin absorption and your liver disease. An investigational therapy is one that not approved by the United States Food and Drug Administration (FDA) and is being provided to you under an Investigational New Drug application from the FDA.

Inborn errors of bile acid metabolism have been established as a well recognized cause of neonatal cholestasis and fat-soluble vitamin malabsorption. Although there is extensive experience with metabolic defects in the biosynthetic pathway, few patients have identified with defects in conjugation with taurine or glycine that allows bile acids to become effective detergents. This protocol is designed to study the effect of defects of conjugation of bile acids on growth and fat-soluble vitamin malabsorption. Study subjects will have liver function studies performed, serum and urinary bile acid measurements, vitamin levels, growth measurements, bile acid pool size measurements made by stable isotope dilution mass-spectrometry, and measurements of absorption of two fat-soluble vitamins, tocopherol and vitamin D. Subjects will be treated orally with conjugates of cholic acid with follow-up laboratories performed as an outpatient and then subjects will have all of the initial studies repeated during an inpatient stay 3-12 months after starting treatment. Subjects with previous liver biopsies indicating the presence of significant liver disease will have a repeat liver biopsy after 3-12 months treatment to assess the histologic response to treatment.

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Bile Acid Synthesis Defect
  • Inborn Error of Bile Acid Metabolism
  • Inborn Error of Bile Acid Conjugation
Drug: Glycocholic Acid
10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
Other Names:
  • Glycocholic Acid
  • Conjugated Cholic Acid
Experimental: GlycoCholic Acid, Study Drug
A Phase III, open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
Intervention: Drug: Glycocholic Acid
Setchell KD, Heubi JE, Shah S, Lavine JE, Suskind D, Al-Edreesi M, Potter C, Russell DW, O'Connell NC, Wolfe B, Jha P, Zhang W, Bove KE, Knisely AS, Hofmann AF, Rosenthal P, Bull LN. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency. Gastroenterology. 2013 May;144(5):945-955.e6; quiz e14-5. doi: 10.1053/j.gastro.2013.02.004. Epub 2013 Feb 13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
20
December 2020
December 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Confirmation of a diagnosis of an inborn error of bile acid synthesis/conjugation based upon urine analysis by FAB-MS.
  2. Any age
  3. Participant must be willing and able to comply with study assessments and procedures.
  4. The participant and/or parent/legal guardian must have signed the written informed consent document prior to study start.
Both
up to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01589523
2009-0780
No
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
Not Provided
Principal Investigator: Kenneth D.R. Setchell, Ph.D. Children's Hospital Medical Center, Cincinnati
Principal Investigator: James E. Heubi, M.D. Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP